Market Overview:
The global Lambert-Eaton myasthenic syndrome (LEMS) treatment market is expected to register a CAGR of 7.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of LEMS, rising awareness about LEMS and its diagnosis, and technological advancements in the field of LEMS treatment. Based on type, the potassium channel blockers segment is expected to account for a major share of the global Lambert-Eaton myasthenic syndrome (LEMS) treatment market in 2018. This can be attributed to their ability to improve muscle strength and reduce muscle fatigue in patients with LEMS. Based on application, hospitals are expected to account for a major share of the global Lambert-Eaton myasthenic syndrome (LEMS) treatment market in 2018. This can be attributed to increasing number of hospital admissions owing to increase incidence rate of LEMS across the globe.
Product Definition:
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder that affects the muscles. It occurs when the body's own immune system mistakenly attacks the nerve-muscle junction, which disrupts communication between the nerves and muscles. This can lead to muscle weakness and problems with movement. Lambert-Eaton myasthenic syndrome is treated with medications that suppress the immune system, such as corticosteroids or immunosuppressive drugs.
Potassium Channel Blockers (Amifampridine):
Potassium channel blockers are used to treat Lambert-Eaton myasthenic syndrome. It is also used as an add on therapy for the treatment of post-polio syndrome and chronic muscular atrophy. Potassium channel blockers are more accurately called amifampridine since they were first developed as a drug to treat FAMS rather than LEMS.
Cholinesterase Inhibitor (Pyridostigmine):
Cholinesterase inhibitor (Pyridostigmine) is an anticholinesterase drug that prevents the breakdown of acetylcholine by inhibiting the enzyme that catalyzes the conversion of choline to phosphocholine. It has been used in treatment for myasthenia gravis and post-polio syndrome.
Application Insights:
Based on application, the market is segmented into hospitals, ambulatory surgical centers and others. The hospital segment dominated the overall industry in terms of revenue in 2017. This can be attributed to factors such as a high prevalence of patients suffering from ME/CFS and other myasthenic disorders coupled with increasing awareness among healthcare professionals regarding this disease. According to an article published by NCBI, around 90% of all Lambert-Eaton Myasthenic Syndrome cases are reported from North America and Europe which indicates that majority of the population is getting diagnosed at hospitals or medical facilities within these regions.
The others segment includes home healthcare services, where patients require assistance for daily activities as well as during meals due to their weak muscles caused due to ME/CFS or another myasthenia gravis disorder.
Regional Analysis:
North America dominated the Lambert-Eaton Myasthenic Syndrome treatment market in 2017. This can be attributed to the increasing prevalence of autoimmune diseases, favorable reimbursement scenario, and rising awareness about early diagnosis. Moreover, increasing initiatives by organizations such as The Myasthenia Gravis Foundation of America and National Institute of Neurological Disorders & Stroke (NINDS) to raise awareness about this condition is expected to fuel the regional demand for LEMS drugs over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in government funding for R&D activities pertaining myasthenia gravis disease treatment will also drive growth over this period.
Growth Factors:
- Increasing incidence of Lambert-Eaton Myasthenic Syndrome (LEMS)
- Growing awareness about LEMS and its diagnosis
- Rising demand for better and more effective LEMS treatments
- Availability of government funding for LEMS research and development
- Technological advancements in the field of LEMS treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Lambert-Eaton Myasthenic Syndrome Treatment Market Research Report
By Type
Potassium Channel Blockers (Amifampridine), Cholinesterase Inhibitor (Pyridostigmine), Immune Therapy, Intravenous Immunoglobulin, Plasmapheresis
By Application
Hospitals, Ambulatory Surgical Centers, Others
By Companies
Allergan, Plc., Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd., GlaxoSmithkline, Plc., Jacobus Pharmaceutical Company, Inc., Kawasumi Laboratories, Inc., Merck & Co., Inc., Mitsubishi Pharma Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
174
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Lambert-Eaton Myasthenic Syndrome Treatment Market Report Segments:
The global Lambert-Eaton Myasthenic Syndrome Treatment market is segmented on the basis of:
Types
Potassium Channel Blockers (Amifampridine), Cholinesterase Inhibitor (Pyridostigmine), Immune Therapy, Intravenous Immunoglobulin, Plasmapheresis
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Ambulatory Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan, Plc.
- Biomarin Pharmaceutical, Inc.
- Catalyst Pharmaceuticals, Inc.
- F. Hoffman-La Roche Ltd.
- GlaxoSmithkline, Plc.
- Jacobus Pharmaceutical Company, Inc.
- Kawasumi Laboratories, Inc.
- Merck & Co., Inc.
- Mitsubishi Pharma Corporation
Highlights of The Lambert-Eaton Myasthenic Syndrome Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Potassium Channel Blockers (Amifampridine)
- Cholinesterase Inhibitor (Pyridostigmine)
- Immune Therapy
- Intravenous Immunoglobulin
- Plasmapheresis
- By Application:
- Hospitals
- Ambulatory Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lambert-Eaton Myasthenic Syndrome Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for Lambert-Eaton Myasthenic Syndrome, but there are treatments that can help improve the symptoms. Treatment options may include medication, physical therapy, and surgery.
Some of the major players in the lambert-eaton myasthenic syndrome treatment market are Allergan, Plc., Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd., GlaxoSmithkline, Plc., Jacobus Pharmaceutical Company, Inc., Kawasumi Laboratories, Inc., Merck & Co., Inc., Mitsubishi Pharma Corporation.
The lambert-eaton myasthenic syndrome treatment market is expected to grow at a compound annual growth rate of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lambert-Eaton Myasthenic Syndrome Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lambert-Eaton Myasthenic Syndrome Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lambert-Eaton Myasthenic Syndrome Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lambert-Eaton Myasthenic Syndrome Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Size & Forecast, 2018-2028
4.5.1 Lambert-Eaton Myasthenic Syndrome Treatment Market Size and Y-o-Y Growth
4.5.2 Lambert-Eaton Myasthenic Syndrome Treatment Market Absolute $ Opportunity
Chapter 5 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Type
5.2.1 Potassium Channel Blockers (Amifampridine)
5.2.2 Cholinesterase Inhibitor (Pyridostigmine)
5.2.3 Immune Therapy
5.2.4 Intravenous Immunoglobulin
5.2.5 Plasmapheresis
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Ambulatory Surgical Centers
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Lambert-Eaton Myasthenic Syndrome Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Type
9.6.1 Potassium Channel Blockers (Amifampridine)
9.6.2 Cholinesterase Inhibitor (Pyridostigmine)
9.6.3 Immune Therapy
9.6.4 Intravenous Immunoglobulin
9.6.5 Plasmapheresis
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Ambulatory Surgical Centers
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Lambert-Eaton Myasthenic Syndrome Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Type
10.6.1 Potassium Channel Blockers (Amifampridine)
10.6.2 Cholinesterase Inhibitor (Pyridostigmine)
10.6.3 Immune Therapy
10.6.4 Intravenous Immunoglobulin
10.6.5 Plasmapheresis
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Ambulatory Surgical Centers
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Lambert-Eaton Myasthenic Syndrome Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Type
11.6.1 Potassium Channel Blockers (Amifampridine)
11.6.2 Cholinesterase Inhibitor (Pyridostigmine)
11.6.3 Immune Therapy
11.6.4 Intravenous Immunoglobulin
11.6.5 Plasmapheresis
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Ambulatory Surgical Centers
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Lambert-Eaton Myasthenic Syndrome Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Type
12.6.1 Potassium Channel Blockers (Amifampridine)
12.6.2 Cholinesterase Inhibitor (Pyridostigmine)
12.6.3 Immune Therapy
12.6.4 Intravenous Immunoglobulin
12.6.5 Plasmapheresis
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Ambulatory Surgical Centers
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Lambert-Eaton Myasthenic Syndrome Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Type
13.6.1 Potassium Channel Blockers (Amifampridine)
13.6.2 Cholinesterase Inhibitor (Pyridostigmine)
13.6.3 Immune Therapy
13.6.4 Intravenous Immunoglobulin
13.6.5 Plasmapheresis
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Lambert-Eaton Myasthenic Syndrome Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Ambulatory Surgical Centers
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lambert-Eaton Myasthenic Syndrome Treatment Market: Competitive Dashboard
14.2 Global Lambert-Eaton Myasthenic Syndrome Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan, Plc.
14.3.2 Biomarin Pharmaceutical, Inc.
14.3.3 Catalyst Pharmaceuticals, Inc.
14.3.4 F. Hoffman-La Roche Ltd.
14.3.5 GlaxoSmithkline, Plc.
14.3.6 Jacobus Pharmaceutical Company, Inc.
14.3.7 Kawasumi Laboratories, Inc.
14.3.8 Merck & Co., Inc.
14.3.9 Mitsubishi Pharma Corporation
